Paul Tudor Jones Allogene Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 71,752 shares of ALLO stock, worth $172,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,752

Holding current value

$172,204

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $209,515 - $403,963	71,752 New	71,752 $320,000
Q3 2023 Nov 15, 2023	BUY	$3.17 - $5.96 $200,137 - $376,284	63,135 Added 581.19%	73,998 $234,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $49,209 - $73,216	10,863 New	10,863 $53,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $338,183 - $668,544	60,175 Added 352.87%	77,228 $486,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $175,986 - $294,675	17,053 New	17,053 $184,000

Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $1.16 Million - $2.1 Million	-171,247 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $760,073 - $1.52 Million	99,356 Added 138.2%	171,247 $1.56 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $943,928 - $1.76 Million	71,891 New	71,891 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $2.08 Million - $2.73 Million	-98,912 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $2.32 Million - $3.54 Million	98,912 New	98,912 $2.58 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $312,574 - $472,922	-12,120 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $30,212 - $52,009	1,197 Added 10.96%	12,120 $306,000
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $1.28 Million - $1.77 Million	-39,476 Reduced 78.33%	10,923 $412,000
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $926,837 - $2.72 Million	50,399 New	50,399 $2.16 Million

Others Institutions Holding ALLO

# of Institutions

164

Shares Held

106M

Call Options Held

97.5K

Put Options Held

45.6K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $345M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account